Symyoo was designated as the Korea coordinating center to run a multinational phase III clinical trial, which was the first NIH/NINDS study (ATACH 2: Antihypertensive Treatment of Acute Cerebral Hemorrhage II) operated in South Korea. The sponsor audit was also conducted to evaluate trial conduct and compliance with the protocol and SOPs without finding any issue when the trial was successfully completed in 2015.